Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models

BACKGROUND: Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Piao, Yuji, Park, Soon Young, Henry, Verlene, Smith, Bryan D., Tiao, Ningyi, Flynn, Daniel L., de Groot, John F.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2016
Ämnen:
Basic and Translational Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998992/
https://ncbi.nlm.nih.gov/pubmed/26965451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now030
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk